AMLX
NASDAQAmylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc. (AMLX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for AMLX, including 3 SEC filings, 2 earnings updates and 2 press releases and news items. The most recent was published Nov 9, 2026.
AMLX rankings
Financial highlights
Full financials- Revenue, FY2025
- $0
- Revenue growth
- -100.0%
- Net income, FY2025
- -$144.74M
- Free cash flow, FY2025
- -$123.48M
- Cash
- $240.09M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks50+75%
2026-05-172026-11-08
Mix3690d
- SEC Filings12(33%)
- Insider12(33%)
- Other5(14%)
- Earnings4(11%)
- Offering2(6%)
- Leadership1(3%)
Activity · 52 weeks10654 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 144 filed by Amylyx Pharmaceuticals Inc.144 - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)
- SECAmylyx Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- SECSEC Form 10-Q filed by Amylyx Pharmaceuticals Inc.10-Q - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- PRAmylyx Pharmaceuticals Reports Third Quarter 2026 Financial ResultsReported positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia; New Drug Application submission planned by end of 2026 remains on track Results from LUCIDITY trial accepted as a late-breaking oral presentation at ObesityWeek® 2026 Annual Meeting on November 15 Strengthened balance sheet through upsized public offering with net proceeds of approximately $545 million Management to host conference call and webcast today at 8:00 a.m. Eastern Time Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today reported financial and business results for the third quarter ended September 30, 2026. "The third quarter w
- PRAmylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH ExpertsAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that it will host an investor event at the ObesityWeek® Annual Meeting on November 15, 2026, at 11:45 a.m. ET, both in-person and virtually. The event will feature Key Opinion Leader (KOL) perspectives on the substantial burden of post-bariatric hypoglycemia (PBH). Additionally, speakers will review the results from the Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with PBH following Roux-en-Y gastric bypass (RYGB) surgery, which will be presented at ObesityWeek. Amylyx’s management team will be joine
- PRAmylyx Pharmaceuticals to Participate in Upcoming November Investor ConferencesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person: Guggenheim 3rd Annual Healthcare Innovation Conference: Fireside Chat on Monday, November 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts Stifel 2026 Healthcare Conference: Fireside chat on Tuesday, November 10, 2026, at 3:20 p.m. ET in New York City, New York A live webcast of both presentations can be accessed under "Events and Presentations" in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be available for replay fo
- PRAmylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its third quarter 2026 financial results on Thursday, November 5, 2026. Amylyx’s senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company’s website, https://investors.amylyx.com/events-p
- INSIDERDirector Milne George M Jr sold $830,904 worth of shares (30,000 units at $27.70) as part of a pre-agreed trading plan (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- PRAmylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual MeetingLate-breaking oral presentation to feature Phase 3 topline data highlighting avexitide’s efficacy and safety Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced it will present two presentations at the upcoming ObesityWeek® 2026 Annual Meeting, taking place November 14-17, 2026, in Washington, D.C. The first late-breaking oral presentation will feature topline results from the Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery. This follows the Company’s announcemen
- SECSEC Form 144 filed by Amylyx Pharmaceuticals Inc.144 - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)
- PRAmylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic ForumAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will present at the Stifel 2026 Virtual Cardiometabolic Forum. The fireside chat will take place on Wednesday, September 30th, 2026, at 9:30 a.m. ET. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the events. About Amylyx Pharmaceuticals At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue wi
- INSIDERCo-Chief Executive Officer Klee Justin B. sold $980,263 worth of shares (30,464 units at $32.18), decreasing direct ownership by 0.84% to 3,613,056 units (SEC Form 4) (for tax liability)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERCo-Chief Executive Officer Cohen Joshua B sold $980,504 worth of shares (30,464 units at $32.19), decreasing direct ownership by 0.84% to 3,613,123 units (SEC Form 4) (tax withholding)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Legal Officer Mazzariello Gina sold $309,506 worth of shares (9,536 units at $32.46), decreasing direct ownership by 5% to 190,838 units (SEC Form 4) to cover taxes4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Financial Officer Frates James M sold $349,821 worth of shares (10,810 units at $32.36), decreasing direct ownership by 4% to 233,625 units (SEC Form 4) to satisfy tax liability4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Medical Officer Bedrosian Camille L sold $324,868 worth of shares (10,028 units at $32.40), decreasing direct ownership by 3% to 278,064 units (SEC Form 4) to satisfy tax liability4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- SECSEC Form 144 filed by Amylyx Pharmaceuticals Inc.144 - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)
- SECSEC Form 144 filed by Amylyx Pharmaceuticals Inc.144 - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)
- PRTortugas Neuroscience Announces Appointment of Jim Frates to Board of DirectorsTortugas Neuroscience ("Tortugas"), a clinical-stage central nervous system (CNS)-focused biotech company developing medicines with clinically validated mechanisms of action in indications with both substantial patient populations and high unmet need, today announced the appointment of Jim Frates to its Board of Directors and as Chair of the Audit Committee. A highly experienced biopharmaceutical leader who has served as chief financial officer (CFO) for multiple public and private biotechnology companies, Frates currently serves as CFO of Amylyx Pharmaceuticals (NASDAQ:AMLX). "Jim’s wealth of experience in CNS drug development, coupled with his deep financial acumen, will be invaluable t
- SECSEC Form 8-K filed by Amylyx Pharmaceuticals Inc.8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- PRAmylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare ConferenceAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will present at the 24th Annual Morgan Stanley Global Healthcare Conference. The fireside chat will take place on Tuesday, September 15th, 2026, at 12:20 p.m. ET. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the events. About Amylyx Pharmaceuticals At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that
- INSIDERDirector Firestone Karen exercised 50,000 shares at a strike of $3.40, increasing direct ownership by 75% to 116,900 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Financial Officer Frates James M was granted 22,807 shares, increasing direct ownership by 10% to 244,435 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERCo-Chief Executive Officer Klee Justin B. was granted 60,039 shares, increasing direct ownership by 2% to 3,643,520 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Legal Officer Mazzariello Gina was granted 21,284 shares, increasing direct ownership by 12% to 200,374 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
AMLX FAQ
11 questionsWhat does Amylyx Pharmaceuticals Inc. do?
Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.What is the latest news on AMLX?
In the last 30 days Quantisnow tracked 7 wire items for AMLX: 3 SEC filings, 2 earnings updates and 2 press releases and news items. The most recent was published on November 9, 2026.What is AMLX revenue?
Amylyx Pharmaceuticals Inc. (AMLX) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is AMLX profitable?
No. Amylyx Pharmaceuticals Inc. reported a net loss of $144.74M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does AMLX have?
Amylyx Pharmaceuticals Inc. reported $240.09M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does AMLX stock trade?
Amylyx Pharmaceuticals Inc. (AMLX) is listed on NASDAQ.What sector and industry is AMLX in?
Amylyx Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Amylyx Pharmaceuticals Inc. go public?
Amylyx Pharmaceuticals Inc. (AMLX) completed its IPO in 2022.What are analysts saying about AMLX?
Across the last 8 analyst actions on Amylyx Pharmaceuticals Inc., there were 3 upgrades and 0 downgrades. The most recent action was from Stifel: Buy with a $21.00 price target on 2026-03-03. Recent price targets range from $7.00 to $21.00.What companies are similar to AMLX?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare AMLX side-by-side with any of them on Quantisnow.How can I track AMLX on Quantisnow?
Quantisnow aggregates Amylyx Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AMLX to receive live email and push alerts on every new disclosure.